Santarus Inc (SNTS)

[surf1944]

4:10AM Santarus provides new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN; showed response rate of 87% (SNTS) 3.21 : Co announces new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema. The median time to beginning of relief of symptoms across treatments for repeat attacks was ~60 minutes with an overall response rate of 87% and no relapses. No product-related adverse reactions were observed during this study. This data from the European open-label study is consistent with previously announced results from an open-label extension study conducted in North America. Additional new open-label data from 34 patients who were treated with RHUCIN for 53 severe acute angioedema attacks involving the upper airways were reported. These results are consistent with previously reported results with RHUCIN for other anatomical locations. The overall response rate in treating these severe and potentially life threatening attacks was 100%; there were no treatment failures and no relapses were reported. In the overall safety analysis of all attacks, including the upper airway attacks, RHUCIN was generally safe and well-tolerated.